Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone effects on renal hemodynamics in essential hypertension
2019-001636-60Phase 2Terminated
- Sponsor
- University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of spironolactone in essential hypertension, sponsored by University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro. Primary endpoint: Renal blood flow. Started May 2019; status: terminated.
02
Drugs
spironolactone
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2019-001636-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001636-60.